Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

NCT04743661 is registered in ClinicalTrials.gov with Pediatric Brain Tumor Consortium as lead sponsor.

NCT NCT04743661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04743661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma
Lead sponsor
Pediatric Brain Tumor Consortium
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 4, 2022
Completion date
September 30, 2027
Enrollment
62 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ependymoma, recurrent medulloblastoma